



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 23, 2006

To: Primary Clinical Research Associates

From: Lori K. Bratvold
Protocol Development Coordinator

Re: N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

The following correction has been made to page 2 of the eligibility checklist: "Last day of corticosteroids" now reads "Corticosteroids start date." Also, the specimen transmittal form has also now been added to the forms packet.

If you have any questions, please feel free to contact me at 507/266-3549.

LB/dg
Enclosure